Bone Marrow Transplantation Market

Bone marrow transplant or hematopoietic stem cell transplant is the surgical procedure to replace impaired bone marrow tissue or bone marrow stem cells with healthy ones. Bone marrow transplant procedure is recommended to treat severe stages of leukemia, Hodgkin and non-Hodgkin lymphomas, multiple myeloma, aplastic and sickle cell anemia, thalassemia etc. As per transplant activity report 2009-2013 from the Center for International Bone and Marrow Transplant Research (CIBMTR), of a total of 88,063 bone marrow transplant procedures performed in the U.S., over 57% procedures were autologous bone marrow transplant procedures.

The report covers the global bone marrow transplant market performance in terms of volume (procedural count) and revenue contribution. The report includes key trends, drivers, restraints, and opportunities influencing the growth of the global bone marrow transplant market over the forecast period. Impact analysis of key growth drivers and restraints, based on the weighted average model, are included to provide clients with crystal clear decision-making insights.

The global bone marrow transplant market growth is mainly driven by factors such as growing prevalence of blood cancers across the globe, expansion of bone marrow transplant registry, growing investment in logistic services, and improvement in survival rate after treatment. Substantially high cost of treatment, lack of reimbursement policies in developing regions, and low availability of bone marrow donors are some factors hampering the growth of the global bone marrow transplant market.

Based on procedure type, the bone marrow transplant market is segmented into autologous bone marrow transplant and allogeneic bone marrow transplant segments. By volume, the autologous bone marrow transplant segment accounted for the major proportion of the overall market share in 2014 and is expected to remain the dominant segment in terms of volume during the forecast period.

By disease indication, the global bone marrow transplant market is classified as leukemia, lymphoma, myeloma, myelodysplasia, myeloproliferative neoplasms, aplastic anemia, solid tumors, sickle cell anemia, thalassemia, and others. The leukemia segment is expected to dominate the market, accounting for a maximum share of the overall market by 2021 end; whereas, revenue from the thalassemia segment is projected to expand at the highest CAGR of 8.9% during the forecast period.

On the basis of the end user, the global bone marrow transplant market is segmented into hospitals, multispecialty clinics, and ambulatory surgical centers (ASC). The hospital end user segment is expected to continue to be dominant, reaching a value of US$ 9,607.4 Mn by 2021 end. In terms of volume, adoption of bone marrow transplant procedures in ambulatory surgical centers is expected to increase by 1.3X globally over the forecast period.

By region, the market in Europe is expected to be dominant in the global bone marrow transplant market in terms of volume throughout the forecast period. North America and Latin America markets are expected to gain significant market share over the forecast period, due to increasing ratio of BMT specialists to that of bone marrow transplant seeking patients in these regions. The MEA market is expected to witness sluggish growth during the forecast period partly due to the relatively low presence of bone marrow transplant centers.

The global bone marrow transplant market is segmented as follows:

By Procedure:

• Autologous Bone Marrow Transplant
• Allogeneic Bone Marrow Transplant

By Disease Indication:

• Leukemia
• Lymphoma
• Myeloma
• Myelodysplasia
• Myeloproliferative Neoplasms
• Aplastic Anemia
• Solid tumors
• Sickle cell Anemia
• Thalassemia
• Others

By End User:

• Hospitals
• Multispecialty Clinics
• Ambulatory Surgical Centers

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • Italy
  • France
  • U.K.
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America
• MEA
  • GCC Countries
  • South Africa
  • Rest of MEA

Key features included in this report:

• Drivers and restraints of the bone marrow transplant market
• Pipeline analysis and key developments in the market
• Analysis of business strategies of key players
• Bone marrow transplant market estimates and forecast

Bone marrow transplant refers to the replacement of diseased or damaged bone marrow with healthy tissue or bone marrow stem cells in order to treat blood cancer or various cases of anemia. Depending on the source of bone marrow or stem cells, bone marrow transplant procedures are classified as peripheral stem cell transplant (PSCT) or conventional bone marrow transplant. Based on procedure type, the bone marrow transplant market has been segmented into autologous bone marrow transplant and allogeneic bone marrow transplant segments. On the basis of disease indication, the market is classified into segments viz. leukemia, lymphoma, myeloma, myelodysplasia, myeloproliferative neoplasms, aplastic anemia, solid tumors, sickle cell anemia, thalassemia, and others. As per end user, bone marrow transplant market is segmented into hospitals, multispecialty clinics, and ambulatory surgical centers (ASC).

Revenue from the global bone marrow transplant market is projected to expand at a steady CAGR of 3.9% over forecast period 2015–2021 and is expected to be valued at US$10.3 Bn by the end of 2021. Among other markets globally, the market in Europe is expected to remain dominant in terms of value and volume throughout the forecast period.

Major factors driving the growth of the global bone marrow transplant market include increasing the prevalence of blood cancers and anemia, expanding bone marrow transplant registries, growing investment in logistic services, and increasing survival rate after treatment. Moreover, factors such as advances in technology, increasing per capita healthcare expenditure, and improvement in healthcare infrastructure are also expected to fuel the growth of the global bone marrow transplant market. However, shortage of bone marrow donors, uncertainty about reimbursement, and the high cost of treatment are the major factors expected to hamper the growth of the global bone marrow transplant market.

Owing to relatively less involvement of risks, autologous bone marrow transplant procedures are being adopted at a faster rate. Hence by procedure type, autologous bone marrow transplant segment accounted for the major proportion of the overall market volume in 2014 and is expected to remain the leading segment in terms of volume during the forecast period. By disease indication, the leukemia segment is expected to dominate the market, accounting for 26.5% share of the overall market revenue by 2021 end. Revenue contribution from the thalassemia segment is projected to expand at the highest CAGR of 8.9% during the forecast period.

Based on regional segmentation, the market in Europe is expected to continue to lead the global market due to increasing number of bone marrow transplant centers and expansion of bone marrow registry. The MEA market is expected to witness sluggish growth during the forecast period partly due to the relatively low presence of bone marrow transplant centers in the region. Latin America market revenue is expected to expand at healthy CAGR of 6.0% due to increasing density of bone marrow transplant centers.

Top players in bone marrow transplantation market covered in this report are Lonza Group Ltd., Merck Millipore Corporation, Sanofi-Aventis LLC, AllCells LLC, STEMCELL Technologies, and American Type Culture Collection (ATCC) Inc. Companies need to launch innovative products to leverage potential opportunities expected to be created by the global bone marrow transplant market.

Key market players covered in this report include:

• Lonza Group Ltd.
• Merck Millipore Corporation.
• Sanofi-Aventis LLC.
• AllCells LLC.
• STEMCELL Technologies.
• American Type Culture Collection (ATCC) Inc.
• Other.

Major players in the bone marrow transplant market are focusing on emerging markets instead of mature markets such as North America and Europe. These companies are more focused towards expanding their presence in clinical applications by introducing stem cell therapy products for use in humans.